Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 14, 2025

Abatacept Improves Post-Transplant Survival and Reduces Endothelial Injury Syndromes in Beta-Thalassemia major.

View Full Paper
Ask AI
Bookmark
Share

Authors

PKPooja KhandelwalCincinnati Children's Hospital Medical CenterAIAzada IbrahimovaCincinnati Children's Hospital Medical CenterALAdam LaneCincinnati Children's Hospital Medical Center

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows abatacept significantly lowers endothelial injury syndromes and acute GVHD in children with beta thalassemia post-HSCT.

Key Points

  • Abatacept cohort had a 100% thalassemia-free survival rate compared to 71% in controls, indicating strong outcomes.
  • Acute grade II-IV GVHD rates were significantly lower in the abatacept group (0%) compared to the control group (35%), highlighting its efficacy.
  • The incidence of endothelial injury syndromes was reduced to 16% in the abatacept cohort versus 64% in the control group, suggesting it limits complications after transplant.
  • Analysis included 64 children with TDT, all receiving standard conditioning before HSCT, with a median follow-up of 1915 days.

Cite This Study

Khandelwal et al. (2025) studied this question.

synapsesocial.com/papers/68d42047713b0b5dfea68bf9https://doi.org/10.1182/bloodadvances.2025017197
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced dose post-transplant cytoxan (Intermediate -Dose) in combination with abatacept after matched unrelated donor transplant for high -risk hematological malignancy may reduce treatment related mortality and risk of relapse.2025
  2. 2Abatacept in combination with post-transplant cyclophosphamide and tacrolimus may improve survival and non-relapse mortality without increasing relapse risk after allogeneic stem cell transplantation2025
  3. 3Data from FDA Approval Summary: Abatacept for the Prophylaxis of Acute GVHD2025
  4. 4Post-transplant cyclophosphamide, abatacept, and vedolizumab for the prevention of graft-versus-host disease after hematopoietic stem cell transplantation in children with acute leukemia: results of a prospective study2025
  5. 5A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial2025 · 1 citations